Pharming Group N.V. Files 6-K for Q4 2023 Update

TL;DR

Pharming Group dropped their Q4 2023 financials on 3/14. Check the 6-K.

AI Summary

Pharming Group N.V. filed a Form 6-K on March 14, 2024, to furnish a press release dated the same day as Exhibit 99.1. The filing does not contain specific financial figures or operational details within the provided text, but indicates it is related to their fourth-quarter 2023 financial information.

Why It Matters

This filing provides an update on Pharming Group's financial performance for the fourth quarter of 2023, which is crucial for investors to assess the company's recent results and future prospects.

Risk Assessment

Risk Level: low — The filing is a routine submission of a press release and does not contain new material risks or significant negative developments.

Key Players & Entities

• Pharming Group N.V. (company) — Registrant
• 001-39822 (dollar_amount) — Commission File Number
• March 14, 2024 (date) — Filing Date

FAQ

From the Filing

0001828316-24-000003.txt : 20240314 0001828316-24-000003.hdr.sgml : 20240314 20240314063337 ACCESSION NUMBER: 0001828316-24-000003 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240314 FILED AS OF DATE: 20240314 DATE AS OF CHANGE: 20240314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 24747864 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 pharminggroup4q2023financi.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated March 14, 2024. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group reports fourth quarter and full year 2023 financial results SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Sijmen de Vries Name: Sijmen de Vries Title: CEO Date: March 14, 2024 2 Pharming Group reports fourth quarter and full year 2023 financial results • Full year 2023 total revenues increased by 19% to US$245.3 million • Record fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to US$227.1 million • Strong start to Joenja® (leniolisib) launch with 81 patients on paid therapy in the U.S. nine months following launch and full year 2023 revenues of US$18.2 million • Overall cash and marketable securities increased to US$215.0 million at the end of 2023 from US$208.7 million at the end of 2022 • Progressed leniolisib development for APDS in additional geographies and for pediatric patients, and leniolisib indication expansion to primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kδ signaling • 2024 total revenue guidance of US$280 million – US$295 million (14% – 20% growth) • Pharming to host a conference call today at 13:30 CET (8:30 am EDT) Leiden, The Netherlands, March 14, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2023. Chief Executive Officer, Sijmen de Vries commented: “We are pleased to have delivered an excellent year in which we transformed Pharming into a multi-product, commercial rare disease biopharmaceutical company. We grew RUCONEST® revenues by 10% in 2023. T